-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Immix Biopharma, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2021 to Q3 2024.
- Immix Biopharma, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $257K, a 37.5% increase year-over-year.
- Immix Biopharma, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $1.06M.
- Immix Biopharma, Inc. annual Nonoperating Income (Expense) for 2023 was $572K.
- Immix Biopharma, Inc. annual Nonoperating Income (Expense) for 2022 was -$497.000, a 100% increase from 2021.
- Immix Biopharma, Inc. annual Nonoperating Income (Expense) for 2021 was -$23M, a 3304% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)